135 results match your criteria: "Switzerland S.Y.; and The J. Craig Venter Institute[Affiliation]"
Circulation
May 2020
Institute for Health Metrics and Evaluation (S.Y., C.O.J., C.M.B., S.I.H., A.H.M., M.R.N., G.A.R.), University of Washington, Seattle.
Background: Nonrheumatic valvular diseases are common; however, no studies have estimated their global or national burden. As part of the Global Burden of Disease Study 2017, mortality, prevalence, and disability-adjusted life-years (DALYs) for calcific aortic valve disease (CAVD), degenerative mitral valve disease, and other nonrheumatic valvular diseases were estimated for 195 countries and territories from 1990 to 2017.
Methods: Vital registration data, epidemiologic survey data, and administrative hospital data were used to estimate disease burden using the Global Burden of Disease Study modeling framework, which ensures comparability across locations.
Automated patch clamp (APC) instruments enable efficient evaluation of electrophysiologic effects of drugs on human cardiac currents in heterologous expression systems. Differences in experimental protocols, instruments, and dissimilar site procedures affect the variability of IC values characterizing drug block potency. This impacts the utility of APC platforms for assessing a drug's cardiac safety margin.
View Article and Find Full Text PDFAnesthesiology
June 2020
From the Department of Anesthesiology, Zhujiang Hospital of Southern Medical University, Guangzhou, China (H.F.Z., F.X.L., H.B.L., S.Y.X.) Faculty of Anesthesiology, Changhai Hospital, Naval Medical University, Shanghai, China (L.B., J.B., X.D.) Institute of Anesthesiology and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (Y.L., S.S., X.C., S.Y.) Department of Anesthesiology, Yale University School of Medicine, New Haven, Connecticut (L.M.).
The coronavirus disease 2019, named COVID-19 officially by the World Health Organization (Geneva, Switzerland) on February 12, 2020, has spread at unprecedented speed. After the first outbreak in Wuhan, China, Chinese anesthesiologists encountered increasing numbers of infected patients since December 2019. Because the main route of transmission is via respiratory droplets and close contact, anesthesia providers are at a high risk when responding to the devastating mass emergency.
View Article and Find Full Text PDFSci Rep
March 2020
Department of Medicine, Division of Cardiology, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, 02215, USA.
Endothelial cells (ECs) display remarkable plasticity during development before becoming quiescent and functionally mature. EC maturation is directed by several known transcription factors (TFs), but the specific set of TFs responsible for promoting high-resistance barriers, such as the blood-brain barrier (BBB), have not yet been fully defined. Using expression mRNA data from published studies on ex vivo ECs from the central nervous system (CNS), we predicted TFs that induce high-resistance barrier properties of ECs as in the BBB.
View Article and Find Full Text PDFACS Cent Sci
February 2020
Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
G protein-coupled receptors play essential roles in cellular processes such as neuronal signaling, vision, olfaction, tasting, and metabolism. As GPCRs are the most important drug targets, understanding their interactions with ligands is of utmost importance for discovering related new medicines. In many GPCRs, an allosteric sodium ion next to the highly conserved residue D has been proposed to stabilize the inactive receptor state by mediating interactions between transmembrane helices.
View Article and Find Full Text PDFNeurol Genet
February 2020
Department of Neurology (C.S.), Friedrich-Baur-Institute, Ludwig-Maximilians-University Munich; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Institute of Human Genetics (C.N.), Department of Medical Genetics, University of Göttingen, Germany; Department of Pediatrics (E.F.), Salzburg State Hospitals (SALK) and Paracelsus Medical University; Division of Clinical Genetics Salzburg State Hospitals and Paracelsus Medical University, Salzburg, Austria; Department of Neurology (S.Y., F.F.), Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China; Mitochondrial Medicine Frontier Program (R.D.G., M.J.F.), Children's Hospital of Philadelphia; Division of Human Genetics (R.D.G.), Department of Pediatrics, University of Pennsylvania Perelman School of Medicine Philadelphia; Department of Pediatrics (R.D.G.), Perelman School of Medicine, University of Pennsylvania; Institute of Medical Genetics and Applied Genomics (J.P.), University of Tübingen, Germany; Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research (J.P.), University of Tübingen, Germany; Children's Hospital (P.F.), Klinikum Reutlingen, Reutlingen; Department of Neurology (C.K.), University Hospital Bonn; Medical Genetic Center (S.K.), Munich; Department of Neurodegeneration (L.S., M.S.), Hertie Institute for Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (DZNE) (L.S.), Tübingen; Department of General Pediatrics (F.D.), Neonatology and Pediatric Cardiology, University Children's Hospital, Heinrich-Heine University, Duesseldorf, Germany; Division of Pediatric Neurology (G.M.S.), University Children's Hospital Zurich, Switzerland; Department of Neurology (B.B.), Friedrich-Baur-Institute, Ludwig-Maximilians-University Munich, Germany; Department of Pediatrics (J.A.M.), Salzburg State Hospitals (SALK) and Paracelsus Medical University, Salzburg, Austria; Department of Neurology (A.A.), Friedrich-Baur-Institute, Ludwig-Maximilians-University Munich, Germany; Medical Genetic Center (A.A.), Munich; Institute of Medical Genetics and Applied Genomics (T.B.H.), Tübingen, Germany; Institute of Human Genetics (H.P.), Technische Universität München, Munich, Germany; Institute of Human Genetics (H.P.), Helmholtz Center Munich, Neuherberg, Germany; Department of Pediatrics (S.B.W.), Salzburg State Hospitals (SALK) and Paracelsus Medical University, Salzburg, Austria; Institute of Human Genetics, Technische Universität München, Munich, Germany; Institute of Human Genetics (S.B.W.), Helmholtz Center Munich, Neuherberg, Germany; Center for Medical Genetics (K.M.), and Department of Metabolism, Chiba Children's Hospital, Chiba, Japan; and Department of Neurology (T.K.), Friedrich-Baur-Institute, Ludwig-Maximilians-University Munich; German Center for Neurodegenerative Diseases (DZNE) (T.K.), Munich; Munich Cluster for Systems Neurology (SyNergy) (T.K.), Ludwig Maximilians University Munich, Germany.
Objective: To delineate the phenotypic and genotypic spectrum in carriers of mitochondrial mutations in a large international cohort.
Methods: We analyzed in detail the clinical, genetical, and neuroimaging data from 132 mutation carriers from national registries and local databases from Europe, USA, Japan, and China.
Results: We identified 113 clinically affected and 19 asymptomatic individuals with a known pathogenic mutation.
Ther Innov Regul Sci
September 2020
Certara, Princeton, NJ, USA.
Background: Pediatric regulations enacted in both Europe and the USA have disrupted the pharmaceutical industry, challenging business and drug development processes, and organizational structures. Over the last decade, with science and innovation evolving, industry has moved from a reactive to a proactive mode, investing in building appropriate structures and capabilities as part of their business strategy to better tackle the challenges and opportunities of pediatric drug development.
Methods: The EFGCP Children's Medicines Working Party and the IQ Pediatric working group have joined their efforts to survey their member company representatives to understand how pharmaceutical companies are organized to fulfill their regulatory obligations and optimize their pediatric drug development programs.
Mycobiology
October 2019
Key Laboratory for Plant Diversity and Biogeography of East Asia, Kunming Institute of Botany, CAS, Kunming, China.
Two new species of the lichen genus are discovered in China, namely An. C. Yin & Li S.
View Article and Find Full Text PDFNeuron
February 2020
Center for NeuroGenetics, Department of Molecular Genetics and Microbiology, Genetics Institute, McKnight Brain Institute, Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL 32610, USA. Electronic address:
The intronic C9orf72 G4C2 expansion, the most common genetic cause of ALS and FTD, produces sense- and antisense-expansion RNAs and six dipeptide repeat-associated, non-ATG (RAN) proteins, but their roles in disease are unclear. We generated high-affinity human antibodies targeting GA or GP RAN proteins. These antibodies cross the blood-brain barrier and co-localize with intracellular RAN aggregates in C9-ALS/FTD BAC mice.
View Article and Find Full Text PDFCirc Heart Fail
December 2019
Lee Kong Chian School of Medicine (C.L., S.T.L., M.H.Y.T., M.S.Y.T., M.D.K., N.S.T., W.W., M.A.F., W.S., X.W.), Nanyang Technological University Singapore.
Background: Despite its established significance in fibrotic cardiac remodeling, clinical benefits of global inhibition of TGF (transforming growth factor)-β1 signaling remain controversial. LRG1 (leucine-rich-α2 glycoprotein 1) is known to regulate endothelial TGFβ signaling. This study evaluated the role of LRG1 in cardiac fibrosis and its transcriptional regulatory network in cardiac fibroblasts.
View Article and Find Full Text PDFStroke
December 2019
From the Department of Radiology (N.K., J.M.O., B.K.M., M.A., M.D.H., M.G.), University of Calgary, AB, Canada.
Background and Purpose- The American Heart Association and the American Stroke Association guidelines for early management of patients with ischemic stroke offer guidance to physicians involved in acute stroke care and clarify endovascular treatment indications. The purpose of this study was to assess concordance of physicians' endovascular treatment decision-making with current American Heart Association and the American Stroke Association stroke treatment guidelines using a survey-approach and to explore how decision-making in the absence of guideline recommendations is approached. Methods- In an international cross-sectional survey (UNMASK-EVT), physicians were randomly assigned 10 of 22 case scenarios (8 constructed with level 1A and 11 with level 2B evidence for endovascular treatment and 3 scenarios without guideline coverage) and asked to declare their treatment approach (1) under their current local resources and (2) assuming there were no external constraints.
View Article and Find Full Text PDFStroke
September 2019
Department of Clinical Neurosciences, University of Calgary, Canada (B.K.M., M.A., M.M.F., A.M.D., M.D.H., M.G.).
Background and Purpose- Little is known about the real-life factors that clinicians use in selection of patients that would receive endovascular treatment (EVT) in the real world. We sought to determine patient, practitioner, and health system factors associated with therapeutic decisions around endovascular treatment. Methods- We conducted a multinational cross-sectional web-based study comprising of 607 clinicians and interventionalists from 38 countries who are directly involved in acute stroke care.
View Article and Find Full Text PDFStroke
August 2019
Second Department of Neurology, Attikon Hospital, National and Kapodistrian University of Athens, School of Medicine, Greece (C.L., L.P., G.T.).
To define the efficacy of venetoclax with extended follow-up and identify clinical or biological treatment effect modifiers, updated data for previously treated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) enrolled in 4 early-phase trials were pooled. Rates of response, complete remission (CR/CRi), and undetectable minimal residual disease (U-MRD) were analyzed for all patients (n = 436) and for those patients who were planned to receive 400 mg/day monotherapy (n = 347). Univariate and multiple regression analyses were performed to identify the pretreatment factors associated with response rates and duration of response (DoR).
View Article and Find Full Text PDFNat Chem Biol
February 2019
Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
The identification of activating mutations in NOTCH1 in 50% of T cell acute lymphoblastic leukemia has generated interest in elucidating how these mutations contribute to oncogenic transformation and in targeting the pathway. A phenotypic screen identified compounds that interfere with trafficking of Notch and induce apoptosis via an endoplasmic reticulum (ER) stress mechanism. Target identification approaches revealed a role for SLC39A7 (ZIP7), a zinc transport family member, in governing Notch trafficking and signaling.
View Article and Find Full Text PDFN Engl J Med
November 2018
From the Barts Cancer Institute, Queen Mary University of London, London (P.S.); Perlmutter Cancer Center, New York University School of Medicine, New York (S.A.); the Department of Medicine, University of California, San Francisco, San Francisco (H.S.R.), and Genentech, South San Francisco (L.M., S.Y.C., R.F.) - both in California; University Hospital Heidelberg, Heidelberg, Germany (A.S.); Centro de Pesquisa em Oncologia, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre (C.H.B.), and the University of São Paulo, São Paulo (R.H.) - both in Brazil; Aichi Cancer Center Hospital, Nagoya, Japan (H.I.); the Department of Medical Oncology, Institut Curie, Paris (V.D.); Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea (S.-A.I.); Florida Cancer Specialists and Research Institute, New Port Richey (G.S.W.); Roche, Basel, Switzerland (V.H., A.H.); Dana-Farber Cancer Institute, Boston (E.P.W.); Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia (S.L.); and the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore (L.A.E.).
Background: Unresectable locally advanced or metastatic triple-negative (hormone-receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) breast cancer is an aggressive disease with poor outcomes. Nanoparticle albumin-bound (nab)-paclitaxel may enhance the anticancer activity of atezolizumab.
Methods: In this phase 3 trial, we randomly assigned (in a 1:1 ratio) patients with untreated metastatic triple-negative breast cancer to receive atezolizumab plus nab-paclitaxel or placebo plus nab-paclitaxel; patients continued the intervention until disease progression or an unacceptable level of toxic effects occurred.
Cell Death Dis
October 2018
Novocure Israel, Haifa, Israel.
Tumor Treating Fields (TTFields), an approved treatment modality for glioblastoma, are delivered via non-invasive application of low-intensity, intermediate-frequency, alternating electric fields. TTFields application leads to abnormal mitosis, aneuploidy, and increased cell granularity, which are often associated with enhancement of autophagy. In this work, we evaluated whether TTFields effected the regulation of autophagy in glioma cells.
View Article and Find Full Text PDFNat Commun
April 2018
Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.
The balance between stem cell quiescence and proliferation in skeletal muscle is tightly controlled, but perturbed in a variety of disease states. Despite progress in identifying activators of stem cell proliferation, the niche factor(s) responsible for quiescence induction remain unclear. Here we report an in vivo imaging-based screen which identifies Oncostatin M (OSM), a member of the interleukin-6 family of cytokines, as a potent inducer of muscle stem cell (MuSC, satellite cell) quiescence.
View Article and Find Full Text PDFNat Commun
March 2018
Department of Biochemistry, University of Lausanne, 1066, Epalinges, Switzerland.
The B cell survival factor (TNFSF13B/BAFF) is often elevated in autoimmune diseases and is targeted in the clinic for the treatment of systemic lupus erythematosus. BAFF contains a loop region designated the flap, which is dispensable for receptor binding. Here we show that the flap of BAFF has two functions.
View Article and Find Full Text PDFPLoS One
November 2017
Poultry Research Foundation, Sydney School of Veterinary Science, Faculty of Science, The University of Sydney, Camden, Australia.
A total of 360 male Ross 308 broiler chickens were used in a feeding study to assess the influence of macronutrients and energy density on feed intakes from 10 to 31 days post-hatch. The study comprised ten dietary treatments from five dietary combinations and two feeding approaches: sequential and choice feeding. The study included eight experimental diets and each dietary combination was made from three experimental diets.
View Article and Find Full Text PDFStroke
August 2017
From the Stroke Research Centre, UCL Institute of Neurology, London, United Kingdom (A.C., D.W., D.J.W.); Hemorrhagic Stroke Research Group, Massachusetts General Hospital, Boston (A.C.); Departments of Neurology and Radiology, Hôpital Sainte-Anne, Université Paris Descartes, France (G.T., C.O., M.E.-G., J.-C.B.); Department of Neurology, the 2nd Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China (S.Y., M.L.); Department of Neurology and Center for Stroke Research, Charite Universitätsmedizin, Berlin, Germany (J.F.S., H.E., C.H.N.); Department of Diagnostic and Interventional Neuroradiology, and Neurology, Inselspital, University Hospital Bern, Switzerland (P.P.K.-G., M.E.-K., H.P.M., S.J.); Department of Neurology, Tokai University School of Medicine, Japan (W.T., Y.M., S.T.); Department of Neurology, University of Arizona, Tucson (C.S.K.); UCLA Comprehensive Stroke Center, Geffen School of Medicine, Los Angeles (J.L.S.); Univ. Lille, Inserm, CHU Lille, U1171, Degenerative and Vascular Cognitive Disorders, France (A.S., S.M., C.C.); Department of Neurology, Austin Health and Florey Institute, Heidelberg, Victoria, Australia (V.T.); Department of Statistical Science, University College London, United Kingdom (Z.F., G.A.); Department of Medicine (Neurology), McMaster University and Population Health Research Institute, Hamilton, Ontario, Canada (A.S.); Stanford Stroke Center, Palo Alto, CA (G.W.A.); Division of Neurology, Stroke and Cerebrovascular Health Program, University of British Columbia Hospital, Vancouver, Canada (O.R.B.); Lysholm Department of Neuroradiology, National Hospital, London, United Kingdom (H.R.J.); Department of Neurological Science, Nippon Medical School Graduate School of Medicine, Tokyo, Japan (J.A., K.K.); and Department of Rehabilitation Medicine, the Jikei University School of Medicine, Tokyo, Japan (W.K.).
Background and Purpose- We assessed whether the presence, number, and distribution of cerebral microbleeds (CMBs) on pre-intravenous thrombolysis MRI scans of acute ischemic stroke patients are associated with an increased risk of intracerebral hemorrhage (ICH) or poor functional outcome. Methods- We performed an individual patient data meta-analysis, including prospective and retrospective studies of acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Using multilevel mixed-effects logistic regression, we investigated associations of pre-treatment CMB presence, burden (1, 2-4, ≥5, and >10), and presumed pathogenesis (cerebral amyloid angiopathy defined as strictly lobar CMBs and noncerebral amyloid angiopathy) with symptomatic ICH, parenchymal hematoma (within [parenchymal hemorrhage, PH] and remote from the ischemic area [remote parenchymal hemorrhage, PHr]), and poor 3- to 6-month functional outcome (modified Rankin score >2).
View Article and Find Full Text PDFEnviron Microbiol
August 2017
Department of Gut Ecology, Host-Microbe Interaction Group, Nestlé Research Center, Lausanne, Switzerland.
In 1890, Robert Koch has formulated postulates describing what criteria a parasite has to fulfil to qualify as an aetiological agent for an infectious disease. Since then Koch's postulates have experienced reformulations by nearly every generation of microbiologists reflecting new discoveries changing the understanding of infectious diseases pathogenesis. The latest addition to this discussion is the role of the host commensal microbiota in turning infections into disease.
View Article and Find Full Text PDFAsian Spine J
February 2017
Musculoskeletal Education and Research Center (MERC), A Division of Globus Medical, Inc., Audubon, PA, USA.
Study Design: Researchers created a proper type II dens fracture (DF) and quantified a novel current posterior fixation technique with spacers at C1-C2. A clinical case study supplements this biomechanical analysis.
Purpose: Researchers explored their hypothesis that spacers combined with posterior instrumentation (PI) reduce range of motion significantly, possibly leading to better fusion outcomes.
Stroke
March 2017
From the Stroke Unit and Division of Cardiovascular Medicine, University of Perugia, Italy (M.P., G. Agnelli, V.C., C.B., N.F., A.A., M.V., M. Acciarresi, C.D., M.G.M., L.A.C., A. Procopio); Department of Neurology, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece (G.T., K.V.); International Clinic Research Center, St Anne's University Hospital Brno, Czech Republic (G.T.); Second Department of Neurology, "Attikon" Hospital, University of Athens, School of Medicine, Greece (G.T., C.L., M. Chondrogianni); Division of Stroke and Cerebrovascular Diseases, Department of Neurology, The Warren Alpert Medical School of Brown University, Providence, RI (K.L.F., P.T., S.Y.); Neurology Unit, Stroke Unit, Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia, Italy (M.Z.); Medical School and Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (A.H.A.-R., K.R.L.); Unità Semplice Dipartimentale (USD) Stroke Unit, DAI di Neuroscienze, AOUI Verona, Italy (P.B., M. Carletti, A.R., M. Cappellari); Department of Neurology, Helsinki University Central Hospital, Finland (J.P., L.T., T. Tatlisumak); Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg and Department of Neurology, Sahlgrenska University Hospital, Sweden (T. Tatlisumak); Department of Neurology, Ospedale San Paolo, Savona, Italy (F.B.); Neurologia d'urgenza e Stroke Unit, Istituto Clinico Humanitas, Rozzano, Milano, Italy (S. Marcheselli); Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Italy (A. Pezzini, L.P., A. Padovani); Internal Medicine, Santa Maria Nuova Hospital, Firenze, Italy (L.M., V. Vannucchi); Department of Neurology, Keimyung University School of Medicine, Daegu, South Korea (S.-I.S.); Stroke Unit, AOU Senese, Siena, Italy (G.L.); SC Medicina e Chirurgia d'Accettazione e d'Urgenza, Pontedera o Volterra, Azienda USL Toscana Nord Ovest, Italy (R.T., F. Guideri, M. Acampa, G. Martini); Department of Medicine, University of Thessaly, Larissa, Greece (G.N., E.K., G. Athanasakis, K.M.); Department of Internal Medicine, Ospedale Civile di Livorno, Italy (N.M.); Stroke Unit, Jazzolino Hospital, Vibo Valentia, Italy (D.C., F. Galati); Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, Italy (S.S., A. Carolei, C.T.); UO Gravi Cerebrolesioni, San Giovanni Battista Hospital, Foligno (F.C.); Department of Clinical and Experimental Medicine, Insubria University, Varese, Italy (W.A., M.B., G.C.); S.C. di Neurologia e S.S. di Stroke Unit, ASST di Mantova, Mantova, Italy (G.S., A. Ciccone); Stroke Unit, Neuroscience Department, University of Parma, Italy (U.S.); Stroke Unit, Dipartimento Geriatrico Riabilitativo, University of Parma, Italy (L.D.); Clinica Neurologica, Azienda Ospedaliero-Universitaria, Pisa, Italy (M. Mancuso, M. Maccarrone, G.O., N.G., G.G., A. Chiti); Neurologia, Ospedale Apuano, Massa Carrara, Italy (G.O., M.G.); Stroke Unit, Department of Neurology, Santa Corona Hospital, Pietra Ligure (Savona), Italy (T. Tassinari); Stroke Unit, Department of Neurology, Insubria University, Varese, Italy (M.L. D.L., G.B.); Abteilung für Neurologie, Oberschwabenklinik gGmbH, Ravensburg, Germany (C.R.); Stroke Unit, Ospedale di Portogruaro, Portogruaro (Venice), Italy (A.B., S.D.); Department of Neurology and Psychiatry, Sapienza University of Rome, Italy (D.T., F.L., A. Pieroni); U.O. Neurologia Stroke Unit, Ospedale SM delle Croci, Ravenna, Italy (E.M.L.); Stroke and Neurorehabilitation Unit, MC 'Universal Clinic 'Oberig' Kyiv, Ukraine (Y.F.); Stroke Unit, Metropolitan Hospital, Piraeus, Greece (O.K.); 2nd Department of Neurology, AHEPA University Hospital, Thessaloniki, Greece (T.K.); Stroke Unit, Ospedale Civico, Palermo, Italy (S. Monaco, M.M.B.); Stroke Unit, University of Debrecen, Hungary (L.C., L.S.); Stroke Unit, Department of Neurology, Sant'Andrea Hospital, La Spezia, Italy (A. Chiti, E.G., M.D.S.); Divisione di Neurologia, Ospedale Galliera, Genoa, Italy (M.D.S.); Department of Internal Medicine, Ospedale Civile di Piacenza, Italy (D.I., D.Z.); City Hospital No. 1, Novosibirsk State Medical University, Russia (B.D., V. Volodina); Centre Cérébrovasculaire, Service de Neurologie, Département des Neurosciences Cliniques Centre Hopitalier Universitaire Vaudois, Lausanne (Switzerland) (P.M.); Department of Neurology, Born Bunge Institute, Antwerp University Hospital, Antwerp, Belgium (P.V.); Department of Neurology, Dresden University Stroke Center, Germany (K.B., L.-P.P., J.K., U.B., J.G.); Neurology, Hamad Medical Corporation, Doha, Qatar (D.D., G. Melikyan, F.I., N.A.); and Department of Neurology, Evangelismos Hospital, Athens (V.G.).
Background And Purposes: This study was designed to derive and validate a score to predict early ischemic events and major bleedings after an acute ischemic stroke in patients with atrial fibrillation.
Methods: The derivation cohort consisted of 854 patients with acute ischemic stroke and atrial fibrillation included in prospective series between January 2012 and March 2014. Older age (hazard ratio 1.
Circ Cardiovasc Interv
November 2016
From the Department of Internal Medicine, Sanbon Hospital, Wonkwang University College of Medicine, Gunpo, Korea (S.-Y.L.); Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea (M.-K.H., D.-H.S., J.-S.K., B.-K.K., Y.-G.K., D.C., Y.J.); Cardiovascular Research Institute (M.-K.H., D.-H.S., J.-S.K., B.-K.K., Y.-G.K., D.C., Y.J.) and Severance Biomedical Science Institute (M.-K.H., Y.J.), Yonsei University College of Medicine, Seoul, Korea; Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, Korea (H.-S.K.); Department of Cardiology, Bern University Hospital, Switzerland (M.V.); Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy (A.C.); Department of Cardiology, CHU de la Cavale Blanche, Brest, France (M.G.); Dipartimento Cardio-Toraco-Vascolare, University of Bologna, Italy (T.P.); and Columbia University Medical Center/NewYork-Presbyterian Hospital and the Cardiovascular Research Foundation, NY (G.W.S.).
Background: There is general agreement that the optimal duration of dual antiplatelet therapy (DAPT) in patients treated with drug-eluting stents should be individualized. We hypothesized that the extent of coronary artery disease may affect the clinical outcomes of DAPT.
Methods And Results: We pooled patient-level data from 5 large, randomized trials comparing short-term DAPT with prolonged therapy.